伴侣动物药物市场（按动物类型、产品类型、剂型、通路、疾病和最终用户划分）－2025-2030 年全球预测

伴侣动物药物市场预计到 2024 年将达到 175.3 亿美元，2025 年将达到 188.5 亿美元，到 2030 年将达到 272.6 亿美元，复合年增长率为 7.63%。

主要市场统计数据
基准年2024年	175.3亿美元
预计2025年	188.5亿美元
预测年份 2030	272.6亿美元
复合年增长率（%）	7.63%

为下一代伴侣动物药物奠定基础，以满足宠物和马匹不断变化的健康需求

伴侣动物製药产业已成为全球动物保健的重要支柱，体现了人类与宠物之间日益加深的连结。近年来，宠物饲养数量的增加、动物福利意识的增强以及兽医学的进步，推动了对创新治疗方法的需求。如今，饲主寻求的解决方案不仅能治疗疾病，还能改善宠物的整体健康，这促使製造商不断扩展产品线。同时，监管机构正在推出更为细緻的指导方针，以确保安全性和有效性，从而提高了产品开发和核准的门槛。

透过技术进步和不断变化的监管环境，引领伴侣动物医学格局的颠覆性发展

在技​​术创新、流行病学概况变化和法律规范不断发展的推动下，伴侣动物製药领域正在经历重大变革时期。老年宠物族群中慢性病的盛行率不断上升，这刺激了人们对长期治疗方法的研究，并鼓励人们采用缓释性注射剂和新型生技药品。同时，数位健康平台、远端医疗服务和人工智慧主导的诊断技术开始影响处方行为和依从性，在兽医和饲主之间建立一个更具互动性的生态系统。

评估2025年美国关税调整及其对伴侣动物保健产品供应链的广泛影响

2025年，美国进口关税大幅调整，为伴侣动物药品领域的公司带来了新的考量。原料和成品剂型关税的提高推高了销售成本，迫使製造商重新考虑筹资策略和定价结构。一些供应商正在透过多元化采购网络、将生产转移到关税优惠的司法管辖区或加快对本地生产的投资来缓解这些压力。

发现全面的市场区隔洞察，揭示不同的动物类型、产品、配方、通路和最终用户动态

深入研究市场区隔，可以发现重要的细微差别，从而指南伴侣动物药物的策略规划。就动物类型而言，每个物种——禽类、猫科动物、犬科动物和马科动物——都呈现出独特的治疗需求、监管途径和产品采用率。犬科动物和猫科动物在创新重点和商业活动方面占据主导地位，而马科动物健康产品通常因性能和育种应用而具有溢价。禽类市场虽然相对小众，但其预防性疫苗和特殊抗菌药物正受到越来越多的关注。

战略区域展望重点关注美洲、欧洲、中东和非洲地区以及亚太地区市场的需求驱动因素和成长机会

区域展望凸显了美洲、欧洲、中东和非洲以及亚太市场差异化的成长轨迹和竞争态势。在美洲，宠物饲养趋势和优惠的报销制度支撑了对高端疗法和新型生技药品的强劲需求。北美市场受益于简化的监管审查和消费者对先进疗法的强烈投资意愿，而拉丁美洲经济体正在逐步扩大其兽医基础设施，扩大基本药物的可及性。

透过策略倡议和合作塑造伴侣动物医学未来的关键创新者和主要企业的简介

产业领导者正在采取各种策略性倡议，以巩固其在伴侣动物药物领域的地位。领先的公司正在扩大研究中心，并日益注重内部生技药品能力，以加速单株抗体和新型疫苗平台的开发。与生技公司的策略性收购和合作协议凸显了他们对创新的动力，并加快了最先进治疗的上市时间。

为伴侣动物药物开发行业的领导者提供可行的策略建议，以推动成长和创新

产业领导者可以立即采取行动，抓住新兴机会，应对关键挑战。首先，优先投资先进生技药品和精准医疗，将使其产品组合更具差异化，并满足日益增长的针对性解决方案需求。将研发资源分配给单株抗体、下一代疫苗和基因治疗平台，将使企业始终处于科学创新的前沿。

描述用于准确可靠地分析伴侣动物药物市场动态的严格调查方法

本报告采用一手资料调查方法，以确保获得可靠且稳健的见解。二手资料研究涵盖对学术期刊、行业白皮书、监管文件和公司文献的深入研究，旨在建立对市场动态、法律规范和技术进步的基础理解。

总结性见解总结了主要发现并强调了对伴侣动物製药行业的战略意义

伴侣动物製药产业正处于关键的十字路口，生技药品的进步、疾病负担的转变以及消费行为的演变正在重塑竞争格局。从动物类型到最终用户，关键细分领域揭示了差异化的成长路径，而区域动态则凸显了不同的市场成熟度和策略要务。 2025年关税调整的累积影响凸显了韧性供应链和积极主动的政策参与的重要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 宠物拥有量的增加和宠物的人性化
• 普及可早期发现宠物慢性疾病的家用诊断套件
• 针对宠物遗传疾病的口服基因治疗发展迅速
• 新型抗菌肽的出现可对抗宠物抗药性感染疾病
• 营养补充品组合在老年宠物健康管理中越来越受欢迎
• 预防性宠物保健需求不断增长
• 电子商务和直接面向消费者的兽医药局的成长
• 宠物专用药物配方及给药的进展
• 扩大伴侣动物抗生素管理计画的远距远端医疗处方服务
• 製药和生物技术公司合作推进动物基因治疗

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

8. 伴侣动物药物市场（依动物类型）

• 鸟
• 猫
• 狗
• 马

9. 伴侣动物药物市场（依产品类型）

• 抗菌剂
  • 抗生素
  • 抗真菌药物
  • 抗寄生虫药
• 生物製药
  • 干扰素
  • 单株抗体
  • 疫苗
• 生长促进剂
• 药品和饲料添加剂
• 製药

10. 伴侣动物药物市场（按剂型）

• 注射
• 液体
• 修补
• 粉末
• 喷
• 药片

11. 伴侣动物药物市场（依分销管道）

• 线上零售商
• 药局连锁
• 兽医诊所

12. 伴侣动物药物市场（依疾病状况）

• 慢性病
• 胃肠道问题
  • 结肠炎
  • 发炎性肠道疾病
• 感染疾病
  • 细菌感染疾病
  • 病毒感染

13. 伴侣动物药物市场（依最终用户）

• 动物收容所和救援组织
• 宠物饲养员/训练员
• 宠物饲主
• 兽医

14.美洲伴侣动物药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 欧洲、中东和非洲伴侣动物药物市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16. 亚太地区伴侣动物药物市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Alivira Animal Health Limited
  • Ashish Life Science Pvt. Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health, LLC
  • Hester Biosciences Limited
  • Hipra Laboratories, SA
  • Indian Immunologicals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Meiji Group
  • Merck KGaA
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Orion Corporation
  • Phibro Animal Health Corporation
  • SkyEc Pharmaceuticals Private Limited
  • Stanex Drugs and Chemicals Pvt Ltd.
  • Tianjin Ringpu Biotechnology Co., Ltd.
  • Veko Care
  • Vetbiolix
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Companion Animal Pharmaceuticals Market was valued at USD 17.53 billion in 2024 and is projected to grow to USD 18.85 billion in 2025, with a CAGR of 7.63%, reaching USD 27.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 17.53 billion
Estimated Year [2025]	USD 18.85 billion
Forecast Year [2030]	USD 27.26 billion
CAGR (%)	7.63%

Setting the Stage for Next Generation Companion Animal Pharmaceuticals to Address Evolving Health Needs in Pets and Equine Populations

The companion animal pharmaceuticals sector has emerged as a critical pillar in global animal health, reflecting the deepening bond between humans and their pets. In recent years, increased pet ownership, heightened awareness of animal welfare, and advances in veterinary medicine have driven the demand for innovative therapies. Owners now seek solutions that not only treat diseases but also enhance overall well-being, prompting manufacturers to expand their pipelines. Meanwhile, regulatory agencies have introduced more nuanced guidelines to ensure safety and efficacy, elevating the bar for product development and approval.

Amid these dynamics, stakeholders are navigating complex supply chains that span continents, balancing cost pressures with the imperative to maintain consistent product quality. Technological breakthroughs in biologics, targeted therapies, and digital health platforms offer new avenues for growth, yet they also demand robust R&D investments and agile commercialization strategies. Against this backdrop, the industry is challenged to anticipate shifting disease patterns, integrate novel delivery systems, and respond to evolving consumer expectations.

This executive summary distills the most significant trends reshaping the market, from transformative scientific innovations to the ripple effects of global trade policies. It provides an authoritative foundation for decision makers seeking a comprehensive understanding of the current landscape, enabling them to pinpoint strategic opportunities and chart a course toward sustainable growth.

Navigating Disruptive Transformations Reshaping the Companion Animal Pharmaceuticals Landscape Through Technological Advancements and Regulatory Evolution

The companion animal pharmaceuticals landscape is undergoing profound transformations driven by technological innovation, changing epidemiological profiles, and evolving regulatory frameworks. Increased prevalence of chronic diseases among aging pet populations has spurred research into long-term therapeutic regimens, encouraging the adoption of sustained-release injectables and novel biologics. Concurrently, digital health platforms, telemedicine services, and AI-driven diagnostics are beginning to influence prescribing behaviors and compliance, creating a more interactive ecosystem between veterinarians and pet owners.

Regulatory authorities across key markets have accelerated approval pathways for breakthrough therapies, especially those leveraging monoclonal antibodies, gene therapies, and personalized medicine approaches. These expedited processes, however, require manufacturers to invest heavily in rigorous safety and efficacy studies, raising the stakes of clinical development. Meanwhile, the demand for natural and holistic solutions has elevated interest in nutraceuticals and alternative modalities, compelling traditional pharmaceutical companies to broaden their scope.

Shifting consumer attitudes are also redefining value propositions, as pet owners increasingly prioritize convenience, transparency, and data-driven care. Subscription models for prescription renewals, home delivery of medicated feed additives, and integrated health tracking applications are reshaping distribution dynamics. In this environment of simultaneous disruption and opportunity, companies must embrace agility, foster cross-sector partnerships, and align innovation pipelines with emerging market realities to stay competitive.

Assessing the 2025 United States Tariff Adjustments and Their Far-Reaching Implications for Companion Animal Health Product Supply Chains

In 2025, sweeping adjustments to United States import tariffs have created a new calculus for companies operating in the companion animal pharmaceuticals sector. Heightened duties on raw materials and finished formulations have increased cost of goods sold, compelling manufacturers to reexamine sourcing strategies and pricing structures. Some suppliers have mitigated these pressures by diversifying their procurement networks, shifting production to tariff-friendly jurisdictions, or accelerating local manufacturing investments.

These tariff realignments have also rippled through global supply chains, as contract manufacturers and active pharmaceutical ingredient producers adapt to changing trade flows. Extended lead times and elevated freight costs have underscored the need for strategic inventory management, with several organizations adopting just-in-time models to balance stock availability against cash flow constraints. At the same time, hedging strategies and long-term supplier agreements have emerged as vital tools to stabilize margins and ensure continuity of supply.

Pricing pressures introduced by tariffs have in some cases accelerated consolidation among smaller players, as they struggle to absorb escalating expenses. Larger firms with integrated global footprints are better positioned to leverage volume advantages and internalize production costs. For decision makers, these developments underscore the importance of scenario planning, flexible manufacturing capabilities, and proactive engagement with policymakers to navigate the evolving trade environment effectively.

Unlocking Comprehensive Market Segmentation Insights That Illuminate Diverse Animal Types, Products, Formulations, Channels, and End User Dynamics

A deep dive into market segmentation reveals critical nuances that guide strategic planning across companion animal pharmaceuticals. When examining animal type, each species-whether birds, cats, dogs, or horses-exhibits distinct therapeutic requirements, regulatory pathways, and product adoption rates. Canine and feline segments dominate in terms of innovation focus and commercial activity, while equine health often commands premium pricing driven by performance and breeding applications. Avian markets remain comparatively niche but are attracting attention for preventive vaccines and specialized antimicrobials.

Exploring product type highlights the layered complexity of pharmaceutical offerings. Antimicrobials encompass antibiotics, antifungals, and antiparasitics, which address both therapeutic and prophylactic needs. Biologics, including interferons, monoclonal antibodies, and vaccines, are rapidly gaining share due to their precision and safety profiles. Growth promoters and medicated feed additives continue to play a vital role in livestock-adjacent segments, while traditional pharmaceutical drugs span a broad spectrum of small-molecule therapies.

Formulation preferences further influence market entry strategies, as injectables, liquids, patches, powders, sprays, and tablets each present unique stability and administration considerations. Distribution channel analysis underscores the rise of online retailers alongside established pharmacy chains and veterinary clinics, reshaping access points and influencing margin structures. Disease condition analysis shows chronic conditions accounting for sustained treatment regimens, gastrointestinal issues such as colitis and inflammatory bowel disease driving demand for targeted interventions, and infectious diseases-bacterial and viral-inspiring robust vaccine pipelines. Finally, the end user landscape, comprising animal shelters and rescue organizations, pet breeders and trainers, individual pet owners, and veterinary professionals, dictates specific marketing and education approaches to maximize engagement and adherence.

Revealing Strategic Regional Perspectives Highlighting Demand Drivers and Growth Opportunities Across the Americas, EMEA, and Asia-Pacific Markets

Regional perspectives offer a window into differentiated growth trajectories and competitive dynamics across the Americas, EMEA, and Asia-Pacific. In the Americas, strong pet ownership trends and favorable reimbursement frameworks support robust demand for premium therapeutics and novel biologics. North American markets benefit from streamlined regulatory reviews and high consumer willingness to invest in advanced treatments, while Latin American economies are gradually expanding veterinary infrastructure and broadening access to essential medicines.

Within Europe, Middle East and Africa, regulatory harmonization across the European Union and collaborative initiatives in the Middle East have created a fertile environment for innovation. Growing investments in local biomanufacturing and increasing recognition of animal welfare standards are driving product launches and market penetration. In Africa, strategic partnerships with international organizations are enhancing vaccination campaigns and disease surveillance, laying the groundwork for future pharmaceutical growth.

The Asia-Pacific region is characterized by divergent market maturity, with established markets like Japan and Australia leading in biologics adoption and digital health integration. Rapidly developing economies in Southeast Asia and South Asia are witnessing rising pet ownership and government initiatives to bolster veterinary services. Manufacturers are prioritizing capacity expansions and regulatory alignment to tap into this heterogeneous yet high-potential market landscape.

Profiling Leading Innovators and Key Players Shaping the Future of Companion Animal Pharmaceuticals Through Strategic Initiatives and Collaborations

Industry leaders are deploying a range of strategic initiatives to fortify their positions in the companion animal pharmaceuticals arena. Major players are increasingly focusing on in-house biologics capabilities, expanding research centers to expedite the development of monoclonal antibodies and novel vaccine platforms. Strategic acquisitions and collaborative agreements with biotechnology firms underscore an appetite for innovation and an acceleration of time-to-market for cutting-edge therapies.

Several key organizations have prioritized sustainability, integrating eco-friendly manufacturing processes and reducing carbon footprints within their supply chains. At the same time, digital transformation efforts, such as data analytics for real-world evidence and AI-driven drug discovery, are reshaping R&D paradigms. Partnerships between pharmaceutical companies and veterinary telehealth providers are creating seamless patient journeys, boosting adherence and enabling remote monitoring of treatment outcomes.

These market leaders also demonstrate agility in response to regulatory shifts, maintaining dedicated teams for policy advocacy and compliance. By fostering open dialogue with regulatory bodies, they secure early insight into changing guidelines, ensuring their product pipelines align with emerging requirements. Together, these strategic moves highlight a proactive approach to innovation, sustainability, and stakeholder engagement that will define success in the evolving companion animal pharmaceuticals ecosystem.

Delivering Actionable Strategic Recommendations to Propel Growth and Innovation for Industry Leaders in Companion Animal Pharmaceutical Development

Industry leaders can take immediate action to harness emerging opportunities and address critical challenges. First, prioritizing investment in advanced biologics and precision therapies will differentiate portfolios and meet growing demand for targeted solutions. Allocating R&D resources to monoclonal antibodies, next-generation vaccines, and gene therapy platforms can position organizations at the forefront of scientific innovation.

Simultaneously, optimizing global supply chains through diversification of manufacturing footprints will mitigate risks associated with escalating tariffs and geopolitical uncertainties. Developing regional production hubs and forging long-term agreements with key suppliers can enhance resilience, reduce lead times, and stabilize cost structures. Leveraging digital supply chain management tools will further improve real-time visibility and decision making.

A third imperative involves deepening customer engagement by integrating digital health solutions and tailored educational programs. Collaborations with telehealth providers, interactive mobile applications, and virtual training for veterinary professionals can elevate brand loyalty and adherence. Finally, aligning corporate sustainability goals with operational practices-such as reducing single-use plastics in packaging or adopting green chemistry principles-will resonate with conscientious consumers and bolster corporate reputation. By executing these strategic recommendations, organizations will be well-equipped to drive growth, enhance innovation, and secure long-term competitive advantage.

Explaining Rigorous Research Methodologies Employed to Analyze Market Dynamics in Companion Animal Pharmaceuticals with Precision and Credibility

The research methodology underpinning this report integrates a blend of primary and secondary approaches to ensure robust and credible insights. Secondary research involved exhaustive reviews of academic journals, industry whitepapers, regulatory filings, and company literature to establish a foundational understanding of market dynamics, regulatory frameworks, and technological advancements.

Primary research complemented these efforts, featuring in-depth interviews with veterinary specialists, pharmaceutical executives, and key opinion leaders. These expert dialogues provided granular perspectives on product development pipelines, commercialization challenges, and evolving end user preferences. Survey data collected from veterinary clinics, pet owners, and distribution partners enriched the analysis of adoption trends and channel performance.

Data triangulation and validation processes were applied throughout to reconcile diverse inputs and fortify the accuracy of findings. Quantitative analyses of historical shipment volumes, trade data, and patent filings were cross-referenced with qualitative insights to derive nuanced interpretations. This rigorous methodology ensures that strategic recommendations are grounded in empirical evidence and aligned with real-world industry conditions.

Concluding Insights That Synthesize Key Findings and Emphasize the Strategic Implications for the Companion Animal Pharmaceutical Industry

The companion animal pharmaceuticals industry stands at a pivotal juncture, where advancements in biologics, shifting disease burdens, and evolving consumer behaviors converge to reshape competitive landscapes. Key segmentations-from animal type to end user-reveal differentiated pathways for growth, while regional dynamics highlight diverse market maturity and strategic imperatives. The cumulative impact of 2025 tariff adjustments underscores the importance of resilient supply chains and proactive policy engagement.

Leading companies are setting the bar through targeted R&D investments, strategic collaborations, and digital health initiatives that enhance patient outcomes and streamline operations. Actionable recommendations emphasize the critical need for biologics innovation, supply chain diversification, digital integration, and sustainability commitments. These strategic priorities will empower industry participants to navigate uncertainty and capitalize on emerging opportunities.

As decision makers chart their course forward, this analysis offers a comprehensive roadmap grounded in rigorous research and expert insight. By synthesizing core findings and prioritizing strategic execution, organizations can secure a competitive edge and contribute to the advancement of companion animal health worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rising pet ownership and humanization of companion animals
• 5.2. Growth of at-home diagnostic kits enabling early detection of chronic conditions in pets
• 5.3. Surge in development of oral gene therapies targeting hereditary disorders in pets
• 5.4. Emergence of novel antimicrobial peptides to combat resistant infections in companion animals
• 5.5. Rising prevalence of nutraceutical combinations in senior pet health management
• 5.6. Increased demand for preventive healthcare in pets
• 5.7. Growth of eCommerce and direct-to-consumer veterinary pharmacies
• 5.8. Advancements in pet-specific drug formulations and delivery methods
• 5.9. Expansion of telemedicine prescribing services for companion animal antibiotic stewardship programs
• 5.10. Collaborative partnerships between pharmaceutical and biotech firms to advance animal gene therapies

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Companion Animal Pharmaceuticals Market, by Animal Type

• 8.1. Introduction
• 8.2. Birds
• 8.3. Cats
• 8.4. Dogs
• 8.5. Horses

9. Companion Animal Pharmaceuticals Market, by Product Type

• 9.1. Introduction
• 9.2. Antimicrobials
  • 9.2.1. Antibiotics
  • 9.2.2. Antifungals
  • 9.2.3. Antiparasitics
• 9.3. Biologics
  • 9.3.1. Interferons
  • 9.3.2. Monoclonal Antibodies
  • 9.3.3. Vaccines
• 9.4. Growth Promoters
• 9.5. Medicated Feed Additives
• 9.6. Pharmaceutical Drugs

10. Companion Animal Pharmaceuticals Market, by Formulation

• 10.1. Introduction
• 10.2. Injectables
• 10.3. Liquids
• 10.4. Patches
• 10.5. Powders
• 10.6. Sprays
• 10.7. Tablets

11. Companion Animal Pharmaceuticals Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Online Retailers
• 11.3. Pharmacy Chains
• 11.4. Veterinary Clinics

12. Companion Animal Pharmaceuticals Market, by Disease Condition

• 12.1. Introduction
• 12.2. Chronic Conditions
• 12.3. Gastrointestinal Issues
  • 12.3.1. Colitis
  • 12.3.2. Inflammatory Bowel Disease
• 12.4. Infectious Diseases
  • 12.4.1. Bacterial Infections
  • 12.4.2. Viral Infections

13. Companion Animal Pharmaceuticals Market, by End User

• 13.1. Introduction
• 13.2. Animal Shelters & Rescue Organizations
• 13.3. Pet Breeders / Trainers
• 13.4. Pet Owners
• 13.5. Veterinarians

14. Americas Companion Animal Pharmaceuticals Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Companion Animal Pharmaceuticals Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Companion Animal Pharmaceuticals Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Alivira Animal Health Limited
  • 17.3.2. Ashish Life Science Pvt. Ltd.
  • 17.3.3. Boehringer Ingelheim International GmbH
  • 17.3.4. Ceva Sante Animale
  • 17.3.5. Chanelle Pharma
  • 17.3.6. Dechra Pharmaceuticals PLC
  • 17.3.7. Eco Animal Health Group PLC
  • 17.3.8. Elanco Animal Health Incorporated
  • 17.3.9. Endovac Animal Health, LLC
  • 17.3.10. Hester Biosciences Limited
  • 17.3.11. Hipra Laboratories, S.A.
  • 17.3.12. Indian Immunologicals Ltd.
  • 17.3.13. Kyoritsu Seiyaku Corporation
  • 17.3.14. Meiji Group
  • 17.3.15. Merck KGaA
  • 17.3.16. Neogen Corporation
  • 17.3.17. Norbrook Laboratories Ltd.
  • 17.3.18. Orion Corporation
  • 17.3.19. Phibro Animal Health Corporation
  • 17.3.20. SkyEc Pharmaceuticals Private Limited
  • 17.3.21. Stanex Drugs and Chemicals Pvt Ltd.
  • 17.3.22. Tianjin Ringpu Biotechnology Co., Ltd.
  • 17.3.23. Veko Care
  • 17.3.24. Vetbiolix
  • 17.3.25. Virbac S.A.
  • 17.3.26. Zoetis Inc.
  • 17.3.27. Zydus Animal Health

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. COMPANION ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHAI
• FIGURE 28. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHSTATISTICS
• FIGURE 29. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHCONTACTS
• FIGURE 30. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COLITIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COLITIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL SHELTERS & RESCUE ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL SHELTERS & RESCUE ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET BREEDERS / TRAINERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET BREEDERS / TRAINERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 95. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 97. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARIANS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARIANS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 111. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 113. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 115. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 117. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 119. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 131. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 133. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 134. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 135. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 136. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 137. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 138. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 139. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 140. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 141. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 142. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 143. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 144. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 145. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 146. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 147. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 148. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 149. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 150. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 151. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 152. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 153. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 154. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 155. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 156. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 157. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 158. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 159. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 160. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 161. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 165. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 166. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 167. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 168. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 169. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 170. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 171. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 172. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 173. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 174. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 175. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 176. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 177. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 178. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 179. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 180. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 181. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 185. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 186. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 187. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 188. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 189. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 190. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 191. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 192. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 193. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 194. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 195. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 196. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 197. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 198. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 199. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 200. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 201. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 203. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 204. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 205. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 207. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 208. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 209. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 210. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 211. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 212. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 213. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 214. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 215. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 216. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 217. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 218. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 219. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 220. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 221. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 245. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 246. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 247. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 249. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 250. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 251. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 252. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 253. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 254. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 255. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 257. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 258. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 259. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 260. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 261. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 262. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 263. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 265. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 266. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 267. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 269. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 270. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 271. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 272. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 273. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 274. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 275. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 276. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 277. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
• TABLE 278. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
• TABLE 279. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
• TABLE 280. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
• TABLE 281. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 282. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 283. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 285. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 286. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 287. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 288. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 289. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
• TABLE 290. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
• TABLE 291. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 292. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
• TABLE 293. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 201